Travere Therapeutics, Inc. (TVTX) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $50.36 (-0.43%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 14, 2026 | Vamil Divan | Guggenheim | $49.00 | -2.7% |
| Sep 10, 2025 | Maury Raycroft | Jefferies | $35.00 | -30.5% |
| Oct 31, 2024 | Liisa Bayko | Evercore ISI | $33.00 | -34.5% |
| Oct 21, 2024 | Mohit Bansal | Wells Fargo | $27.00 | -46.4% |
| Oct 10, 2024 | Liisa Bayko | Evercore ISI | $30.00 | -40.4% |
| Oct 9, 2024 | Jason Zemansky | Bank of America Securities | $20.00 | -60.3% |
| Oct 1, 2024 | Carter Gould | Barclays | $18.00 | -64.3% |
| Sep 27, 2024 | Vamil Divan | Guggenheim | $23.00 | -54.3% |
| Sep 27, 2024 | Ed Arce | H.C. Wainwright | $18.00 | -64.3% |
| Sep 27, 2024 | Greg Harrison | Bank of America Securities | $18.00 | -64.3% |
| Sep 10, 2024 | Ed Nash | Canaccord Genuity | $23.00 | -54.3% |
| Sep 9, 2024 | Vamil Divan | Guggenheim | $12.50 | -75.2% |
| Aug 28, 2024 | Nicole Gabreski | Piper Sandler | $12.00 | -76.2% |
| Aug 2, 2024 | Ed Arce | H.C. Wainwright | $10.00 | -80.1% |
| May 7, 2024 | Ed Nash | Canaccord Genuity | $9.00 | -82.1% |
| Apr 24, 2024 | Ed Arce | H.C. Wainwright | $9.50 | -81.1% |
Top Analysts Covering TVTX
TVTX vs Sector & Market
| Metric | TVTX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 24 | 8 | 19 |
| Target Upside | +50.9% | +153002.0% | +21.5% |
| P/E Ratio | -73.46 | 3.54 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $199M | $219M | $261M | 8 |
| 2027-03-31 | $191M | $210M | $250M | 4 |
| 2027-06-30 | $214M | $236M | $281M | 4 |
| 2027-09-30 | $230M | $253M | $302M | 5 |
| 2027-12-31 | $243M | $267M | $318M | 4 |
| 2028-12-31 | $1.14B | $1.14B | $1.14B | 9 |
| 2029-12-31 | $1.19B | $1.37B | $1.66B | 4 |
| 2030-12-31 | $1.38B | $1.58B | $1.92B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.44 | $0.49 | $0.62 | 4 |
| 2027-03-31 | $0.29 | $0.33 | $0.41 | 2 |
| 2027-06-30 | $0.40 | $0.46 | $0.57 | 2 |
| 2027-09-30 | $0.53 | $0.59 | $0.74 | 2 |
| 2027-12-31 | $0.57 | $0.65 | $0.81 | 2 |
| 2028-12-31 | $2.03 | $3.39 | $5.07 | 6 |
| 2029-12-31 | $3.37 | $4.04 | $5.16 | 4 |
| 2030-12-31 | $4.20 | $5.04 | $6.43 | 2 |
Frequently Asked Questions
What is the analyst consensus for TVTX?
The consensus among 24 analysts covering Travere Therapeutics, Inc. (TVTX) is Buy with an average price target of $70.60.
What is the highest price target for TVTX?
The highest price target for TVTX is $49.00, set by Vamil Divan at Guggenheim on 2026-01-14.
What is the lowest price target for TVTX?
The lowest price target for TVTX is $9.00, set by Ed Nash at Canaccord Genuity on 2024-05-07.
How many analysts cover TVTX?
24 analysts have issued ratings for Travere Therapeutics, Inc. in the past 12 months.
Is TVTX a buy or sell right now?
Based on 24 analyst ratings, TVTX has a consensus rating of Buy (2.00/5) with a +50.9% upside to the consensus target of $70.60.
What are the earnings estimates for TVTX?
Analysts estimate TVTX will report EPS of $0.49 for the period ending 2026-12-31, with revenue estimated at $219M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.